Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
232 participants
INTERVENTIONAL
2013-12-18
2017-09-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
2. To test the hypothesis of a deleterious effect of this release on the expected improvement of insulin-resistance and on the liver inflammation.
3. To determine the level of contamination of morbidly obese patients, with or without metabolic syndrome, compared to a control, non obese population, with special attention to clinical (age, gender, reproductive history, pregnancy, nursing) and biological parameters (insulin-resistance, inflammation).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exploratory Evaluation of the Effect of Cholestyramine on Serum Levels of POPs in Obese Female Patients
NCT05966727
Determinants of Oral Morphine Answer Among Obese Patients Before and After Gastric Bypass
NCT00943969
Metabolomics and Bariatric Surgery in Patients With Metabolically Unhealthy Obesity
NCT06297928
Organic Pollutant Build-Up in Body Fat and Stomach Tissue Linked to Obesity Levels
NCT07126743
Impact of Preoperative Hypocaloric Hyperproteinic Lipid Restricting Diet on Bariatric Surgery
NCT05529199
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In a prospective, multicentric study, we propose to analyse the kinetic of the release of several POPs during rapid and massive weight loss obtained after bariatric surgery. Those POPs have been chosen for their obesogen or diabetogen properties, reported in vitro or in vivo, for their lipophilic nature, and their ubiquitous presence in the home environment and/or into the food chain: bisphenol A (plastics); tributyltin (fungicide, anti-fouling agent or thermic stabilizant); polybrominated diphenyl ethers (PBDE, fire retardants); perchlorated octanoïd acid and its sulphated compounds (PFOA and PFOS, perfluoroalkyls used as surfactant, lubrifiants, and usted in wrappings); and organochorinated compounds such as: PCB153, representing the polychlorinated bisphenyls (electric isolation); hexachlorobenzene (HBC), and several pesticides: DDE, metabolite of DDT, now banned but with a very long half life, hexachlorocyclohexane (HCH), heptachlor, nanochlor and chlordane used in agriculture.
II- Originality and /or new aspect of the project Though suggested by several experimental studies, the role of POP in human obesity remains largely unknown.
There are no or very few papers on the role in humans of the POPs we have selected, but they are supported by animal experimental studies.
The concept of release in the blood stream after weight loss is recent and deserves to be studied.
III- Reasons for the choice of questions (3 maximum) Interest of the results/method to improve knowledge on those questions
1. To study the kinetics of release after bariatric surgery of selected polluants stored in adipose tissue, looking for clinical and/or predictive factors
2. To test the hypothesis of a deleterious effect of this release on the expected improvement of insulin-resistance and on the liver inflammation.
3. To determine the level of contamination of morbidly obese patients, with or without metabolic syndrome, compared to a control, non obese population, with special attention to clinical (age, gender, reproductive history, pregnancy, nursing) and biological parameters (insulin-resistance, inflammation).
IV- Description of the methods/ Calendar The POPs will be measured in serum, urine (for BPA) and in adipose tissue (subcutaneous and visceral) by gas chromatography coupled to mass spectrometry.
Fat mass will be estimated when possible by DEXA (if weight\<150 kg), or by impedancemetry, allowing the calculation of an estimated total body burden for each POP (since they are lipophilic, we will multiply the concentration of each chemical in adipose tissue expressed in ng/g of fat by the total estimated body mass of fat).
The number of patients included will be 250 morbidly obese adults, with or without metabolic syndrome (3 out of 5 classical criteria), eligible for bariatric surgery (125 from Nice undergoing gastric bypass, and 125 from Montpellier undergoing sleeve gastrectomy).
Concentrations of polluants will be measured at baseline and 3, 6 and 12 month after bariatric surgery, and at 18 months as well for patients who will undergo abdominoplasty required by their massive weight loss. Baseline concentrations in obese patients will be compared to those measured in 100 controls, matched for age and gender, with a BMI\<25.
Insulin resistance will be assessed by HOMA-IR, adiponectine and SHBG, inflammation by us CRP, leptin, interleukin 6, TNF alpha, transaminases, gammaGT, alkalin phosphatase.
The redistribution of POPs in serum and adipose tissue, and the estimation of total body burden will be assessed before and after surgery.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
sleeve bariatric surgery
morbidly obese adults, with or without metabolic syndrome eligible for bariatric surgery undergoing sleeve gastrectomy
Lipophilic Organic Polluants dosage
Urinary, blood and fat dosage of Lipophilic Organic Polluants
morbidly obese adults with by pass surgery
morbidly obese adults, with or without metabolic syndrome eligible for bariatric surgery undergoing gastric bypass
Lipophilic Organic Polluants dosage
Urinary, blood and fat dosage of Lipophilic Organic Polluants
non obese
non obese patients
Lipophilic Organic Polluants dosage
Urinary, blood and fat dosage of Lipophilic Organic Polluants
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lipophilic Organic Polluants dosage
Urinary, blood and fat dosage of Lipophilic Organic Polluants
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* health coverage
* mentally competent
* signed consent form
* stable weight over the last three months
* pregnancy
* insulin treated diabetes
* significant weight change over the last three months
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Nice
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Patrick FENICHEL, PhD
Role: PRINCIPAL_INVESTIGATOR
Nice University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nice University Hospital
Nice, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
12-API-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.